vs
Side-by-side financial comparison of Orange County Bancorp, Inc. (OBT) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Orange County Bancorp, Inc. is the larger business by last-quarter revenue ($33.0M vs $18.6M, roughly 1.8× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 37.6%, a 28.1% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 20.6%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 14.3%).
Orange County Bancorp, Inc. is a Delaware-registered bank holding company operating mainly in New York, U.S. It offers a full range of retail and commercial banking services, including deposit accounts, loans and wealth management solutions, serving individual consumers, small and mid-sized corporate clients in its regional footprint.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
OBT vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $33.0M | $18.6M |
| Net Profit | $12.4M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 41.4% | 56.3% |
| Net Margin | 37.6% | 65.7% |
| Revenue YoY | 20.6% | 1808.5% |
| Net Profit YoY | 73.5% | 376.5% |
| EPS (diluted) | $0.94 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $33.0M | $18.6M | ||
| Q3 25 | $33.7M | $334.0K | ||
| Q2 25 | $32.5M | $1.4M | ||
| Q1 25 | $28.0M | $257.0K | ||
| Q4 24 | $27.4M | $977.0K | ||
| Q3 24 | $27.1M | $660.0K | ||
| Q2 24 | $27.9M | $736.0K | ||
| Q1 24 | $25.3M | $1.4M |
| Q4 25 | $12.4M | $12.3M | ||
| Q3 25 | $10.0M | $-8.6M | ||
| Q2 25 | $10.5M | $-6.9M | ||
| Q1 25 | $8.7M | $-5.4M | ||
| Q4 24 | $7.2M | — | ||
| Q3 24 | $3.2M | $-2.8M | ||
| Q2 24 | $8.2M | $-14.5M | ||
| Q1 24 | $9.3M | $411.0K |
| Q4 25 | 41.4% | 56.3% | ||
| Q3 25 | 38.6% | -2516.5% | ||
| Q2 25 | 41.9% | -701.0% | ||
| Q1 25 | 40.3% | -3350.2% | ||
| Q4 24 | 32.8% | — | ||
| Q3 24 | 14.8% | -1563.6% | ||
| Q2 24 | 36.6% | -1255.0% | ||
| Q1 24 | 45.9% | -692.5% |
| Q4 25 | 37.6% | 65.7% | ||
| Q3 25 | 29.7% | -2572.2% | ||
| Q2 25 | 32.2% | -504.8% | ||
| Q1 25 | 31.1% | -2097.7% | ||
| Q4 24 | 26.2% | — | ||
| Q3 24 | 11.8% | -425.5% | ||
| Q2 24 | 29.4% | -1964.4% | ||
| Q1 24 | 36.7% | 29.9% |
| Q4 25 | $0.94 | $0.25 | ||
| Q3 25 | $0.75 | $-0.17 | ||
| Q2 25 | $0.87 | $-0.14 | ||
| Q1 25 | $0.77 | $-0.11 | ||
| Q4 24 | $0.64 | — | ||
| Q3 24 | $0.28 | $-0.06 | ||
| Q2 24 | $0.73 | $-0.30 | ||
| Q1 24 | $0.82 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $284.4M | $49.4M |
| Total Assets | $2.7B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
| Q4 25 | $284.4M | $49.4M | ||
| Q3 25 | $270.1M | $36.4M | ||
| Q2 25 | $252.6M | $44.5M | ||
| Q1 25 | $201.3M | $50.5M | ||
| Q4 24 | $185.5M | $55.1M | ||
| Q3 24 | $193.1M | $58.5M | ||
| Q2 24 | $177.5M | $60.4M | ||
| Q1 24 | $168.7M | $74.1M |
| Q4 25 | $2.7B | $59.0M | ||
| Q3 25 | $2.6B | $51.1M | ||
| Q2 25 | $2.6B | $60.7M | ||
| Q1 25 | $2.6B | $67.9M | ||
| Q4 24 | $2.5B | $90.6M | ||
| Q3 24 | $2.5B | $99.0M | ||
| Q2 24 | $2.5B | $107.8M | ||
| Q1 24 | $2.5B | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.8M | $18.4M |
| Free Cash FlowOCF − Capex | $41.3M | — |
| FCF MarginFCF / Revenue | 125.1% | — |
| Capex IntensityCapex / Revenue | 7.6% | — |
| Cash ConversionOCF / Net Profit | 3.53× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $69.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.8M | $18.4M | ||
| Q3 25 | $30.2M | $-8.7M | ||
| Q2 25 | $-5.0M | $-7.5M | ||
| Q1 25 | $4.8M | $-7.5M | ||
| Q4 24 | $34.6M | $-24.0M | ||
| Q3 24 | $10.2M | $765.0K | ||
| Q2 24 | $9.3M | $-10.9M | ||
| Q1 24 | $2.3M | $-4.0M |
| Q4 25 | $41.3M | — | ||
| Q3 25 | $29.6M | — | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $4.3M | — | ||
| Q4 24 | $32.9M | — | ||
| Q3 24 | $10.0M | — | ||
| Q2 24 | $9.2M | — | ||
| Q1 24 | $2.0M | — |
| Q4 25 | 125.1% | — | ||
| Q3 25 | 87.8% | — | ||
| Q2 25 | -17.5% | — | ||
| Q1 25 | 15.5% | — | ||
| Q4 24 | 120.0% | — | ||
| Q3 24 | 36.7% | — | ||
| Q2 24 | 32.8% | — | ||
| Q1 24 | 7.9% | — |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 6.3% | — | ||
| Q3 24 | 1.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 1.0% | — |
| Q4 25 | 3.53× | 1.50× | ||
| Q3 25 | 3.01× | — | ||
| Q2 25 | -0.47× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 4.83× | — | ||
| Q3 24 | 3.19× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 0.24× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OBT
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
